GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (STU:SG7) » Definitions » Cyclically Adjusted Book per Share

Sage Therapeutics (STU:SG7) Cyclically Adjusted Book per Share : €18.59 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Sage Therapeutics's adjusted book value per share for the three months ended in Mar. 2025 was €6.062. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €18.59 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Sage Therapeutics's average Cyclically Adjusted Book Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-05-10), Sage Therapeutics's current stock price is €5.798. Sage Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €18.59. Sage Therapeutics's Cyclically Adjusted PB Ratio of today is 0.31.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sage Therapeutics was 3.29. The lowest was 0.26. And the median was 1.09.


Sage Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Sage Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Cyclically Adjusted Book per Share Chart

Sage Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 16.56 17.02 19.11

Sage Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.51 18.11 17.62 19.11 18.59

Competitive Comparison of Sage Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Sage Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sage Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Sage Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sage Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=6.062/134.9266*134.9266
=6.062

Current CPI (Mar. 2025) = 134.9266.

Sage Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 6.769 100.684 9.071
201509 6.131 100.392 8.240
201512 5.532 99.792 7.480
201603 8.058 100.470 10.821
201606 7.137 101.688 9.470
201609 9.919 101.861 13.139
201612 9.386 101.863 12.433
201703 7.981 102.862 10.469
201706 6.191 103.349 8.083
201709 4.473 104.136 5.796
201712 9.565 104.011 12.408
201803 18.491 105.290 23.696
201806 19.796 106.317 25.123
201809 18.089 106.507 22.916
201812 16.178 105.998 20.593
201903 22.883 107.251 28.788
201906 20.683 108.070 25.823
201909 18.944 108.329 23.595
201912 16.389 108.420 20.396
202003 14.803 108.902 18.341
202006 12.651 108.767 15.694
202009 10.732 109.815 13.186
202012 29.215 109.897 35.869
202103 28.811 111.754 34.785
202106 27.250 114.631 32.075
202109 26.521 115.734 30.919
202112 25.963 117.630 29.781
202203 24.881 121.301 27.676
202206 23.961 125.017 25.860
202209 23.430 125.227 25.245
202212 19.870 125.222 21.410
202303 17.709 127.348 18.763
202306 15.195 128.729 15.927
202309 12.760 129.860 13.258
202312 12.211 129.419 12.731
202403 10.790 131.776 11.048
202406 9.582 132.554 9.754
202409 8.128 133.029 8.244
202412 7.239 133.157 7.335
202503 6.062 134.927 6.062

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Sage Therapeutics  (STU:SG7) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sage Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5.798/18.59
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Sage Therapeutics was 3.29. The lowest was 0.26. And the median was 1.09.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Sage Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sage Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
55 Cambridge Parkway, Cambridge, MA, USA, 02142
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics Headlines

No Headlines